Clinical Trial Update: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). [Phase 1]

View source ↗

Summary

Phase 1 study evaluating novel immunotherapy combinations in triple negative breast cancer has been terminated; sponsor is Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Immunotherapy combinations (unspecified)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 1 | Status: TERMINATED